Pharmacokinetic, angiographic, and histologic comparison of catheter-directed chemoembolization versus systemic chemotherapy in a canine model

XiaoXing Zhan, Patricia E. Thorpe, Devendra K. Agrawal, HanChao Luo, XiaoQiong Yan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Chemotherapy with selective intraarterial embolization may promote sustained contact of the drug with the tumor and thus could be more effective in the treatment. In this phenomenon, pharmacokinetics of a drug such as mitomycin C (MMC) play a significant role in guiding the therapy. Therefore, we have compared the pharmacokinetics of MMC and assessed angiographic, morphologic, and histologic changes in the kidney following intravenous MMC versus renal artery infusion with and without embolization with embolic agents, Rhizoma Bletillae (RE) and Gelfoam (GF). Dogs randomly divided into four groups underwent selective infusion protocols. Blood samples from renal and common iliac veins were analyzed for MMC levels. Angiography and pathology were performed at 4 days. Intravenous MMC (IV-MMC) caused significantly lower renal vein MMC levels than intraarterial MMC (IA-MMC) and GF+MMC. RB+MMC produced the lowest MMC levels in both veins (p <0.05). Common iliac MMC levels were not significantly different after IV-MMC, IA-MMC, or GF+MMC. Angiographic and histologic studies showed extensive bleeding, necrosis, and vasculitis with thrombosis of the target kidneys after RB+MMC, GF+MMC, or IA-MMC, but not IV-MMC. Selective Rhizoma Bletillae chemoembolization can decrease systemic levels of MMC. Gelfoam does not provide sustained local release of MMC or decrease systemic levels of MMC compared with intravenous infusion. Selective renal MMC infusion without an effective embolic agent does not reduce systemic levels compared with intravenous delivery.

Original languageEnglish
Pages (from-to)1117-1125
Number of pages9
JournalCanadian Journal of Physiology and Pharmacology
Volume74
Issue number10
DOIs
StatePublished - 1996

Fingerprint

Mitomycin
Canidae
Catheters
Pharmacokinetics
Drug Therapy
Absorbable Gelatin Sponge
Kidney
Iliac Vein
Renal Veins
Renal Artery
Vasculitis
Intravenous Infusions

All Science Journal Classification (ASJC) codes

  • Physiology
  • Pharmacology

Cite this

Pharmacokinetic, angiographic, and histologic comparison of catheter-directed chemoembolization versus systemic chemotherapy in a canine model. / Zhan, XiaoXing; Thorpe, Patricia E.; Agrawal, Devendra K.; Luo, HanChao; Yan, XiaoQiong.

In: Canadian Journal of Physiology and Pharmacology, Vol. 74, No. 10, 1996, p. 1117-1125.

Research output: Contribution to journalArticle

@article{73ff7090b8634ff38765291a6fe9fac9,
title = "Pharmacokinetic, angiographic, and histologic comparison of catheter-directed chemoembolization versus systemic chemotherapy in a canine model",
abstract = "Chemotherapy with selective intraarterial embolization may promote sustained contact of the drug with the tumor and thus could be more effective in the treatment. In this phenomenon, pharmacokinetics of a drug such as mitomycin C (MMC) play a significant role in guiding the therapy. Therefore, we have compared the pharmacokinetics of MMC and assessed angiographic, morphologic, and histologic changes in the kidney following intravenous MMC versus renal artery infusion with and without embolization with embolic agents, Rhizoma Bletillae (RE) and Gelfoam (GF). Dogs randomly divided into four groups underwent selective infusion protocols. Blood samples from renal and common iliac veins were analyzed for MMC levels. Angiography and pathology were performed at 4 days. Intravenous MMC (IV-MMC) caused significantly lower renal vein MMC levels than intraarterial MMC (IA-MMC) and GF+MMC. RB+MMC produced the lowest MMC levels in both veins (p <0.05). Common iliac MMC levels were not significantly different after IV-MMC, IA-MMC, or GF+MMC. Angiographic and histologic studies showed extensive bleeding, necrosis, and vasculitis with thrombosis of the target kidneys after RB+MMC, GF+MMC, or IA-MMC, but not IV-MMC. Selective Rhizoma Bletillae chemoembolization can decrease systemic levels of MMC. Gelfoam does not provide sustained local release of MMC or decrease systemic levels of MMC compared with intravenous infusion. Selective renal MMC infusion without an effective embolic agent does not reduce systemic levels compared with intravenous delivery.",
author = "XiaoXing Zhan and Thorpe, {Patricia E.} and Agrawal, {Devendra K.} and HanChao Luo and XiaoQiong Yan",
year = "1996",
doi = "10.1139/cjpp-74-10-1117",
language = "English",
volume = "74",
pages = "1117--1125",
journal = "Canadian Journal of Physiology and Pharmacology",
issn = "0008-4212",
publisher = "National Research Council of Canada",
number = "10",

}

TY - JOUR

T1 - Pharmacokinetic, angiographic, and histologic comparison of catheter-directed chemoembolization versus systemic chemotherapy in a canine model

AU - Zhan, XiaoXing

AU - Thorpe, Patricia E.

AU - Agrawal, Devendra K.

AU - Luo, HanChao

AU - Yan, XiaoQiong

PY - 1996

Y1 - 1996

N2 - Chemotherapy with selective intraarterial embolization may promote sustained contact of the drug with the tumor and thus could be more effective in the treatment. In this phenomenon, pharmacokinetics of a drug such as mitomycin C (MMC) play a significant role in guiding the therapy. Therefore, we have compared the pharmacokinetics of MMC and assessed angiographic, morphologic, and histologic changes in the kidney following intravenous MMC versus renal artery infusion with and without embolization with embolic agents, Rhizoma Bletillae (RE) and Gelfoam (GF). Dogs randomly divided into four groups underwent selective infusion protocols. Blood samples from renal and common iliac veins were analyzed for MMC levels. Angiography and pathology were performed at 4 days. Intravenous MMC (IV-MMC) caused significantly lower renal vein MMC levels than intraarterial MMC (IA-MMC) and GF+MMC. RB+MMC produced the lowest MMC levels in both veins (p <0.05). Common iliac MMC levels were not significantly different after IV-MMC, IA-MMC, or GF+MMC. Angiographic and histologic studies showed extensive bleeding, necrosis, and vasculitis with thrombosis of the target kidneys after RB+MMC, GF+MMC, or IA-MMC, but not IV-MMC. Selective Rhizoma Bletillae chemoembolization can decrease systemic levels of MMC. Gelfoam does not provide sustained local release of MMC or decrease systemic levels of MMC compared with intravenous infusion. Selective renal MMC infusion without an effective embolic agent does not reduce systemic levels compared with intravenous delivery.

AB - Chemotherapy with selective intraarterial embolization may promote sustained contact of the drug with the tumor and thus could be more effective in the treatment. In this phenomenon, pharmacokinetics of a drug such as mitomycin C (MMC) play a significant role in guiding the therapy. Therefore, we have compared the pharmacokinetics of MMC and assessed angiographic, morphologic, and histologic changes in the kidney following intravenous MMC versus renal artery infusion with and without embolization with embolic agents, Rhizoma Bletillae (RE) and Gelfoam (GF). Dogs randomly divided into four groups underwent selective infusion protocols. Blood samples from renal and common iliac veins were analyzed for MMC levels. Angiography and pathology were performed at 4 days. Intravenous MMC (IV-MMC) caused significantly lower renal vein MMC levels than intraarterial MMC (IA-MMC) and GF+MMC. RB+MMC produced the lowest MMC levels in both veins (p <0.05). Common iliac MMC levels were not significantly different after IV-MMC, IA-MMC, or GF+MMC. Angiographic and histologic studies showed extensive bleeding, necrosis, and vasculitis with thrombosis of the target kidneys after RB+MMC, GF+MMC, or IA-MMC, but not IV-MMC. Selective Rhizoma Bletillae chemoembolization can decrease systemic levels of MMC. Gelfoam does not provide sustained local release of MMC or decrease systemic levels of MMC compared with intravenous infusion. Selective renal MMC infusion without an effective embolic agent does not reduce systemic levels compared with intravenous delivery.

UR - http://www.scopus.com/inward/record.url?scp=0030460744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030460744&partnerID=8YFLogxK

U2 - 10.1139/cjpp-74-10-1117

DO - 10.1139/cjpp-74-10-1117

M3 - Article

VL - 74

SP - 1117

EP - 1125

JO - Canadian Journal of Physiology and Pharmacology

JF - Canadian Journal of Physiology and Pharmacology

SN - 0008-4212

IS - 10

ER -